Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476114 | 0.81 | CXCR2 (0.48) | RAB9ANPC1TDP1L3MBTL1MEN1 | |
| SCHEMBL200375 | 0.80 | CYP2C19 (0.54) | CYP2C19GABRA5POLBSMN1; SMN2RAB9A | |
| SCHEMBL202417 | 0.78 | HSD11B1 (0.43) | GABRA5TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL200043 | 0.78 | GABRA5 (0.49) | GABRA5POLBSMN1; SMN2PKMCYP19A1 | |
| SCHEMBL221576 | 0.77 | GABRA5 (0.57) | GABRA5POLBSMN1; SMN2PKMCYP19A1 | |
| SCHEMBL29562227 | 0.77 | GABRA5 (0.57) | GABRA5POLBSMN1; SMN2PKMCYP19A1 | |
| SCHEMBL11549503 | 0.73 | HSPB1 (0.53) | CYP2C19GABRA5POLBSMN1; SMN2PKM | |
| SCHEMBL4615407 | 0.72 | POLB (0.47) | POLBSMN1; SMN2PKMCYP19A1RAB9A | |
| SCHEMBL14659339 | 0.72 | GABRA5 (0.49) | GABRA5POLBSMN1; SMN2PKMCYP19A1 | |
| SCHEMBL30442139 | 0.72 | TDP1 (0.52) | GABRA5POLBSMN1; SMN2CYP19A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088926-B2 | Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2008144604-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CYP2C19 1533/4885GABRA5 299/4885POLB 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.